STLN (Starling Oncology) Cash per Share: $0.30 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STLN Starling Oncology Inc STLN
56 GF Score
Price $5.17
GF Value $2.29
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Starling Oncology Cash per Share?

Starling Oncology STLN +5.56% 56 Cash per Share is $0.30 as of Mar. 2026. GuruFocus rates STLN with a GF Score™ of 56/100 and a GF Value™ of $2.29 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Starling Oncology's Cash per Share for the quarter that ended in Mar. 2026 was $0.30.

Starling Oncology  (NAS:STLN) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Starling Oncology Cash per Share Related Terms

Starling Oncology Cash per Share Historical Data

* Premium members only.

The historical data trend for Starling Oncology's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starling Oncology Cash per Share Chart

Starling Oncology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial 1.56 1.01 1.12 0.66 0.34

Starling Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.33 0.28 0.34 0.30
STLN
56GF Score
Starling Oncology Inc STLN
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starling Oncology Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Starling Oncology's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=33.565/98.9
=0.34

Starling Oncology's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=30.28/100.0
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $0.30 mean?
Starling Oncology (STLN) has a Cash per Share of $0.30 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Starling Oncology and its competitors.
Is Starling Oncology's Cash per Share too high?
Starling Oncology's current Cash per Share is $0.30. Overall, Starling Oncology has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's Cash per Share compare to SRTA and CCRN?
Starling Oncology's Cash per Share of $0.30 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Healthcare Providers & Services company?
A good Cash per Share depends on the Healthcare Providers & Services industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Starling Oncology and its competitors. Starling Oncology's current Cash per Share is $0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Based on GuruFocus' analysis, Starling Oncology (STLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.29, compared to a current price of $5.17 — trading 125.8% above its estimated fair value. The current Cash per Share is $0.30. Starling Oncology's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Starling Oncology (STLN), the current Cash per Share is $0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starling Oncology (STLN) Overvalued in 2026?

Based on GuruFocus' analysis, Starling Oncology stock appears to be overvalued. The current stock price of $5.17 is trading 125.8% above its estimated GF Value™ of $2.29. GuruFocus considers Starling Oncology to be Significantly Overvalued.

Key valuation signals for STLN:

  • Cash per Share: $0.30
  • GF Value™: $2.29 vs. price of $5.17 (125.8% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the STLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starling Oncology Business Description

Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for STLN

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.17
Price
$2.29
GF Value